相关实验视频

Updated: Jan 16, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

将FLT3-ITD分子特征与临床风险因素相结合,改善了急性髓性白血病的风险分层

Kainan Zhang¹, Xiaohang Ma¹, Xiaoxuan Lu¹

¹National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People's Hospital, No. 11 Xizhimen South Street, Beijing, 100044, China.

Annals of hematology

|January 14, 2026

概括

在急性髓性白血病 (AML) 中FLT3-ITD突变影响生存率. 特定的插入部位和高白细胞计数是危险因素,但早期的FLT3抑制剂治疗和移植可以改善结果.

科学领域:

血液学血液学血液学
在瘤学瘤学.
分子生物学分子生物学

背景情况:

类似FMS的氨酸激酶3-内部协同重复 (FLT3-ITD) 是急性髓性白血病 (AML) 的常见突变.
特定FLT3-ITD分子特征的预后意义仍然不完全理解.
确定针对性治疗的预测标志物对于改善AML患者的治疗结果至关重要.

研究的目的:

调查FLT3-ITD分子特征的预后价值在新的AML中.
为了确定插入部位,长度,数量,等位基因比率和变异性等位基因频率对患者存活率的影响.
基于这些分子特征,评估早期FLT3抑制剂治疗和移植的疗效.

主要方法:

使用下一代测序 (NGS) 分析170名新诊断的AML患者的FLT3-ITD突变.
评估了分子特征,包括插入长度,数量,基比 (AR),变异基频率 (VAF) 和插入部位.
总生存率 (OS) 和无事件生存率 (EFS) 在突变特征和治疗干预措施方面进行了分析.

主要成果:

更长的插入长度,更高的AR和更多的突变与更短的OS有关,尽管在统计学上并不显著.
在部区域 (HR) /β1域和柔膜域 (JMD) 的FLT3-ITD插入部位,早期FLT3抑制剂治疗显示出明显更好的结果.
高白细胞计数 (>30 × 109/L) 和HR/β1插入部位是较短的OS的独立风险因素.
早期移植和FLT3抑制剂治疗显著改善了OS和EFS.

结论:

FLT3-ITD的分子特征,特别是插入部位和白细胞数量,可以预测AML的预后.
患有高白细胞计数和HR/β1插入的患者代表高风险亚组.
早期服用FLT3抑制剂,特别是针对特定插入部位,可显著改善存活率,并可指导向治疗决策.

关键词:

急性骨髓性白血病 (AML) 是一种急性骨髓性白血病.在FLT3-ITDD中使用.一个分子分子的分子.预测预后预测预测

更多相关视频

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...